Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

64.78 +1.22 (+1.92%)
Streaming Delayed Price Updated: 1:46 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027 Bio-based Platform Chemicals Market Overview The Bio-based Platform Chemicals Market size is forecast to reach... 
Via iCrowdNewswire
Topics Derivatives
Exposures COVID-19 Derivatives
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
From Gilead Sciences, Inc.
Via Business Wire
On Earth Day, Gilead Marks Strides in Environmental Sustainability
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Emissions
Gilead Sciences Announces First Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Support for the Robert A. Winn Diversity in Clinical Trials Award Program
SOURCE: Gilead Sciences 
Via 3BL Media
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Mom Celebrates Sons' Milestones: Julie's CAR T-cell Therapy Journey
SOURCE: Gilead Sciences 
Via 3BL Media
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
From Gilead Sciences, Inc.
Via Business Wire
The Translatinx Network Helps a Resilient Community 'Live Its Truth'
SOURCE: Gilead Sciences 
Via 3BL Media
Tour for Diversity in Medicine, Gilead Sciences and the Advisory Group to SHC Vaccine Equity Program to Receive Booker T. Washington Award From National Minority Quality Forum
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
From Gilead Sciences, Inc.
Via Business Wire
Four Questions With Anu Osinusi: Gilead's Commitment to People Living With Viral Hepatitis
SOURCE: Gilead Sciences 
Via 3BL Media
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
From Gilead Sciences, Inc.
Via Business Wire
Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
At the Forefront of HIV Health and Healing in Spain: Ferran's Story
SOURCE: Gilead Sciences 
Via 3BL Media
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
From Gilead Sciences, Inc.
Via Business Wire
Hope for Haiti Kicks Off Fourth Annual Hike for Haiti Challenge Campaign to Provide Access to Education and Public Health
Feel-good global movement supported by high-profile ambassadors and brands helping to fund organization's $12M plan for school rebuilding and rehabilitation following the devastating 7.2 magnitude... 
Via Newswire.com
Advocating for Black Women With Triple-Negative Breast Cancer: Ricki's Story
SOURCE: Gilead Sciences 
Via 3BL Media
Claflin University's Deeply Rooted Commitment to Social Justice
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
From Gilead Sciences, Inc.
Via Business Wire
Channeling Her Passion to Spread Awareness About TNBC: LaToya's Journey
SOURCE: Gilead Sciences 
Via 3BL Media
Opinion: Searching for the Next Generation of Sustainable Health Care
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
An Open Letter on Ukraine From Daniel O'Day, Chairman & CEO
SOURCE: Gilead Sciences 
Via 3BL Media
Opinion: Why Corporate Philanthropy Must Stand Against Stigma
SOURCE: Gilead Sciences 
Via 3BL Media
Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead, Orbsen, and Others
Continue reading "Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead,... 
Via Get News
Crohn’s Disease Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – UCB, Abbvie, Genetech, Gilead, Celgene, Millennium Pharma, and Others
Continue reading "Crohn’s Disease Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – UCB, Abbvie, Genetech, Gilead, Celgene, Millennium Pharma, and... 
Via Get News
Opinion: Building an Inclusive World Through Sports, Art, and Culture
SOURCE: Gilead Sciences 
Via 3BL Media
Topics LGBTQ
Exposures Diversity
Keto Benefits And Benefits of Drinking Ketones.
Via Marketers Media
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.